EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program

Leanne M Ward iD, Thomas O Carpenter iD, Hamilton Cassinelli, Pablo Florenzano iD, Erik A Imel, Aliya A Khan, Ben Johnson iD, Erru Yang, Marc Vincent, Heather M Heerssen iD, Zhiyi Li iD, Jill H Simmons

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Leanne M Ward und 11 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada K1H 8L1. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized, Fibroblast Growth Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyowa Kirin Inc., Kyowa Kirin, Ultragenyx Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

X-linked hypophosphatemia (XLH) is a rare disorder characterized by excess fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia, osteomalacia, and rickets.

Objective

To evaluate outcomes up to 3 years following initiation of treatment with anti-FGF23 antibody (burosumab) in a real-world setting among individuals with XLH, stratified by age group, including those excluded from clinical trials (<1, 13-17, and ≥65 years).

Methods

The XLH Disease Monitoring Program is a prospective, longitudinal, long-term-outcomes program for individuals with XLH. This analysis included participants who were burosumab-naive at baseline and who had initiated burosumab between baseline and the Year 1 visit. Changes from baseline in biochemistry, clinical outcomes, and patient-reported outcomes (PROs) were assessed at Year 1 (Y1) and Year 3 (Y3) visits.

Results

Among participants (n = 139), burosumab led to significant and sustained improvements in mean (SD) serum phosphate z-scores at Y1 and Y3 (change from baseline: 1.4 [1.1]; P < .0001 for each timepoint). Among pediatric participants, serum alkaline phosphatase z-scores, Rickets Severity Scores, and patient-reported pain interference declined significantly at Y1 and Y3; non-significant changes were observed in fatigue and physical function mobility. Adults showed significant improvements in PRO measures of pain, stiffness, and physical function, with higher proportions of participants achieving minimal clinically important differences at Y3 vs Y1. Trends observed in overall cohorts were generally consistent across age sub-groups, with statistical significance reached for many endpoints.

Conclusion

This analysis demonstrated the real-world effectiveness of burosumab for XLH, which appears evident across age groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Familial Hypophosphatemic RicketsAntibodies, Monoclonal, HumanizedFibroblast Growth FactorsHumansFibroblast Growth Factor-23FemaleMaleAdolescentAdultChildChild, PreschoolMiddle AgedYoung AdultAgedTreatment OutcomeInfantLongitudinal StudiesProspective StudiesAge FactorsPatient Reported Outcome Measures

Stichwörter der Autor:innen

X-linked hypophosphatemiaburosumabpatient-reported outcomesphosphatereal-world

Substanzen

burosumabFibroblast Growth Factor-23FGF23 protein, humanAntibodies, Monoclonal, HumanizedFibroblast Growth Factors

Autor:innen und Institutionen

  • Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada K1H 8L1.
  • Departments of Pediatric (Endocrinology), and Orthopedics and Rehabilitation, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Department of Endocrinology, Ricardo Gutiérrez Children's Hospital, C1425 Buenos Aires, Argentina.
  • School of Medicine, Pontificia Universidad Católica de Chile, 8331150 Santiago, Chile.
  • Departments of Medicine and Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202-3082, USA.
  • Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON, Canada L8S 4L8.

ORCID-Profile: Leanne M Ward, Thomas O Carpenter, Pablo Florenzano, Ben Johnson, Heather M Heerssen, Zhiyi Li

Förderung

  • Kyowa Kirin Inc.
  • Kyowa Kirin
  • Ultragenyx Pharmaceutical
  • University of Ottawa
  • The Children's Hospital of Eastern Ontario Research Institute
  • The Children’s Hospital of Eastern Ontario Research Institute

Zitieren

APA

Ward, L. M., Carpenter, T. O., Cassinelli, H., Florenzano, P., Imel, E. A., Khan, A. A., Johnson, B., Yang, E., Vincent, M., Heerssen, H. M., Li, Z., & Simmons, J. H. (2026). Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag140

Vancouver

Ward LM, Carpenter TO, Cassinelli H, Florenzano P, Imel EA, Khan AA, et al. Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag140

BibTeX
@article{Ward2026,
  author = {Ward, Leanne M and Carpenter, Thomas O and Cassinelli, Hamilton and Florenzano, Pablo and Imel, Erik A and Khan, Aliya A and Johnson, Ben and Yang, Erru and Vincent, Marc and Heerssen, Heather M and Li, Zhiyi and Simmons, Jill H},
  title = {Real-world effectiveness of burosumab across age groups: X-linked hypophosphatemia (XLH) Disease Monitoring Program},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag140}
}
Kostenlos starten →